Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

GT Biopharma Inc (OP: GTBP )

0.5000 USD UNCHANGED
Last Price Updated: 3:57 PM EST, Feb 10, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.5000
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.5000
Today's Range 0.5000 - 0.5000
52wk Range 0.0900 - 0.7700
Shares Outstanding 50,117,977
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
GT Biopharma Adds University of Wisconsin--Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE™, a Novel NK Cell Therapeutic Cancer Treatment
GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on the development and commercialization of its disruptive, target-directed Natural Killer (NK) cell engager... 
From PR Newswire
GT Biopharma Transfers TriKE™ Manufacturing To Cytovance Biologics In Preparation For Expanded And Multiple Liquid And Solid Tumor Clinical Trials
GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on the development and commercialization of its disruptive, target-directed Natural Killer (NK) cell engager... 
From PR Newswire

Performance

YTD
+16.25%
+16.25%
1 Month
+13.64%
+13.64%
3 Month
+138.10%
+138.10%
6 Month
+212.50%
+212.50%
1 Year
+350.45%
+350.45%

More News

Read More
Personalized Medicine Is The Next Big Trend For Biotech Stocks & 1 Company Could Radically Disrupt The Industry
Tags Market News
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
GT Biopharma Appoints Two New Independent Directors
From PR Newswire
GT Biopharma Announces Eighth Patient Begins Treatment Of GTB-3550
From PR Newswire
GT Biopharma (OTCQB: GTBP) Announces Corporate Update Conference Call
From PR Newswire
GT Biopharma Announces Closing of $23.7 Million Public Offering
From Business Wire News Releases
GT Biopharma Announces TriKE™ For The Treatment Of Breast And GI Cancers
From PR Newswire
GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550 TriKE™ REDUCES CANCER CELLS BY 61.7% FOR A HIGH-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) PATIENT
From PR Newswire
GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital Market
From Business Wire News Releases
GT Biopharma And Cytovance Biologics Announce Milestone Achievement
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.